While some studies found no substantial correlation between TROP2 levels and clinicopathological factors in breast cancer, like age, histologic subtype, tumor grade, stage, lymphovascular invasion, or tumor-infiltrating lymphocytes (TILs) levels (36), the significance of TROP2 as a prognostic factor in breast cancer remains undeniable. This evidence concerns the gene TACSTD2 and neoplasm.